Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/18719
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEl-Hayek, Mohamad-
dc.date.accessioned2017-12-11T19:38:07Z-
dc.date.available2017-12-11T19:38:07Z-
dc.date.issued2017-
dc.identifier.citationEl-Hayek M. A systematic review of dapagliflozin treatment for patients with type 2 diabetes mellitus / M. El-Hayek // Xth International Scientific Interdisciplinary Conference (ISIC) for medical students and young scientists, Ukraine, 24–26 may 2017 : abstract book. – Kharkiv : KhNMU, 2017. – P. 36.ru_RU
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/18719-
dc.description.abstractNew class of drugs for treatment type 2 diabetes mellitus (T2DM) are sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drug are an antihyperglycaemic agents with an insulin-independent mode of action. One of the SGLT2 inhibitors class that used in Ukraine for treatment patients with T2DM is a Dapagliflozin. We try to summarize current evidence from different clinical trials that assess the clinical efficacy and safety of dapagliflozin.ru_RU
dc.language.isoenru_RU
dc.subjectdapagliflozinru_RU
dc.subjecttype 2 diabetes mellitusru_RU
dc.titleA systematic review of dapagliflozin treatment for patients with type 2 diabetes mellitusru_RU
dc.typeThesisru_RU
Appears in Collections:Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 3 та ендокринології

Files in This Item:
File Description SizeFormat 
A systematic .pdf249,57 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.